Resetting Expectations for CAR-T Potency Assessment… “Baby, You Can Drive My CAR”

Time: 2:30 pm
day: Day Two


• ‘Full serial dilution curve’ bioassays have been difficult to establish for cell therapy modalities, but they provide critical assessment of potency/relative potency

• Target cell cytotoxicity assays may well be more MOA reflective than cytokine release bioassays

• This presentation will describe successful utilization of a luciferase-complementation-based cytotoxic assay (Promega HiBiT assay)

• Application of this assay format to support of cellular therapies will be discussed